Oral SERD Adherence HR+/HER2- Breast Cancer

CE

The Pharmacist’s Role in Improving Medication Adherence to Oral SERD Therapy in HR+/HER2- Breast Cancer

Pharmacists: 0.25 contact hour (0.025 CEUs)

Released: February 23, 2024

Expiration: February 22, 2025

Allison Butts
Allison Butts, PharmD, BCOP

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

When counseling a patient with estrogen receptor–positive/HER2-ngative breast cancer with an ESR1 mutation before receiving elacestrant, which initial strategy would you recommend to mitigate nausea and improve adherence to therapy?